UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition
In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and raised the price target from $5.00 to $24.50.
In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's announced bid for Idenix at $24.50/share. We do not expect other bidders for this company or any data to cause the deal to not happen...We are Equal-weight IDIX and have a $24.50 price target, which is driven by Merck's announced acquisition price for Idenix. We do not expect other bidders for Idenix.”
Idenix Pharmaceuticals closed on Monday at $23.80.
Latest Ratings for IDIX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 2014 | UBS | Downgrades | Buy | Neutral |
| Jun 2014 | Baird | Upgrades | Underperform | Neutral |
| Jan 2014 | JMP Securities | Downgrades | Market Perform | Market Underperform |
View More Analyst Ratings for IDIX
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings
